ARIAD to Present at the 28th Annual J.P. Morgan Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 28th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company and its progress in key programs on Wednesday, January 13, 2010 at 7:30 a.m. (PT).

The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. A replay will be available on the ARIAD website approximately twenty-four hours after the presentation and will be archived for three weeks.

About ARIAD

ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines. The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD’s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD’s second internally-discovered product candidate, AP24534, is an investigational pan-BCR-ABL inhibitor completing Phase 1 clinical development in patients with hematological cancers, notably chronic myeloid leukemia. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-?B cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit http://www.ariad.com.